Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab and Rituximab for Primary Membranous Nephropathy
NCT03949855Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2020
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of belimumab in primary membranous nephropathy (PMN) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of Participants in Complete or Partial Remission at 104 weeks. Started Mar 2020; status: recruiting.
02
Drugs
belimumab
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT03949855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949855.